
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

April 26, 2010

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)

Commission File No. 001-33057

CATALYST PHARMACEUTICAL PARTNERS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

Delaware
**(State Or Other Jurisdiction Of
Incorporation Or Organization)**

76-0837053
**(IRS Employer
Identification No.)**

**355 Alhambra Circle, Suite 1370
Coral Gables, Florida 33134**
(Address Of Principal Executive Offices)

(305) 529-2522
(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01 Other Events

On April 26, 2010, the Company issued a press release announcing that it has received notice from The Nasdaq Stock Market (“Nasdaq”) confirming that the Company has regained compliance with the \$1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

The Company had previously announced that it had received notice from Nasdaq on November 13, 2009 that it was not in compliance with the \$1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company was provided with 180 days, or until May 12, 2010, to come into compliance with the rule. On April 26, 2010, Nasdaq confirmed to the Company that, as a result of the Company’s common stock closing with a bid price of at least \$1.00 for at least ten consecutive trading days, the Company has come back into compliance with the rule and the matter is now closed.

A copy of the Company’s press release is Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press release issued by the Company on April 26, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Catalyst Pharmaceutical Partners, Inc.

By: /s/ Jack Weinstein

Jack Weinstein

Vice President, Treasurer and Chief

Financial Officer

Dated: April 26, 2010

Exhibit No.

Description

99.1

Press release issued by the Company on April 26, 2010

**NEWS RELEASE**

For Further Information Contact:

Patrick J. McEnany, Catalyst Pharmaceutical
Chief Executive Officer
(305) 529-2522
pmcenany@catalystpharma.com

FOR IMMEDIATE RELEASE

Melody Carey, Rx Communications Group
Co-President
(917) 322-2571
mcarey@rxir.com

**Catalyst Pharmaceutical Partners Regains Compliance
with NASDAQ Minimum Bid Price Rule**

CORAL GABLES, FL, April 26, 2010 — Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced today that it has received notice from The NASDAQ Stock Market (“NASDAQ”) confirming that the Company has regained compliance with the \$1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

As previously announced, on November 13, 2009 NASDAQ notified the Company that the bid price of its common stock had closed at less than \$1.00 per share over the previous 30 consecutive business days, and, as a result, the Company was not in compliance with Listing Rule 5550(a)(2)(“Rule”). The Company was provided 180 calendar days, or until May 12, 2010, to regain compliance with the Rule.

On April 26, 2010, NASDAQ notified the Company that the closing bid price of its common stock has been at \$1.00 per share or greater for at least 10 consecutive business days. Accordingly, NASDAQ has confirmed to the Company that the Company has regained compliance with the minimum bid price rule and that the matter is now closed.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. Catalyst has two products in development, and is currently evaluating the lead product candidate, CPP-109 (vigabatrin, a GABA aminotransferase inhibitor) for the treatment of cocaine addiction. CPP-109 has been granted “Fast Track” status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction, which indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address an unmet medical need. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. Catalyst is also in the early stages of developing CPP-115, another GABA aminotransferase inhibitor that could be more potent than vigabatrin but may have reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin. Catalyst is planning to develop CPP-115 for several indications, including epilepsy and drug addiction. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to GABA aminotransferase. For more information about the Company, go to www.catalystpharma.com.

###